Serum proprotein convertase subtilisin/kexin type 9 and cell surface low-density lipoprotein receptor evidence for a reciprocal regulation

Circulation

Volumn 127, Issue 24, 2013, Pages 2403-2413

  Tavori, Hagai ^a   Fan, Daping ^d   Blakemore, John L ^a   Yancey, Patricia G ^a   Ding, Lei ^a   Linton, MacRae F ^a,b   Fazio, Sergio ^a,c  

^a Atherosclerosis Research Unit   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VANDERBILT UNIVERSITY   (United States)

^d UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Cholesterol; LDL receptor; Lipoproteins; Mouse model; PCSK9 protein

Indexed keywords

APOLIPOPROTEIN B; CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; MESSENGER RNA; PROPROTEIN CONVERTASE SUBTILISIN KEXIN 9; SERINE PROTEINASE; SUBTILISIN; UNCLASSIFIED DRUG;

ADRENAL GLAND; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL SURFACE; CHOLESTEROL BLOOD LEVEL; GAIN OF FUNCTION MUTATION; IN VITRO STUDY; IN VIVO STUDY; KIDNEY; LIVER; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN METABOLISM; REGULATORY MECHANISM;

CHOLESTEROL; LDL RECEPTOR; LIPOPROTEINS; MOUSE MODEL; PCSK9 PROTEIN;

ANIMALS; CELLS, CULTURED; CHOLESTEROL; DISEASE MODELS, ANIMAL; HUMANS; HYPERCHOLESTEROLEMIA; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; PROPROTEIN CONVERTASES; RECEPTORS, LDL; SERINE ENDOPEPTIDASES; TRANSFECTION;

EID: 84879287631     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.113.001592     Document Type: Article

References (50)

1. Hunt KJ, Resendez RG, Williams K, Haffner S.M., Stern MP; San Antonio Heart Study. National Cholesterol Education Program versus World Health Organization metabolic syndrome in relation to all-cause and cardiovascular mortality in the San Antonio Heart Study. Circulation. 2004;110:1251-1257.
2. Horton JD, Goldstein JL, Brown MS SREBPs: transcriptional mediators of lipid homeostasis. Cold Spring Harb Symp Quant Biol. 2002;67:491-498.
3. Glassberg H, Rader DJ Management of lipids in the prevention of cardiovascular events. Annu Rev Med. 2008;59:79-94.
4. Benjannet S, Rhainds D, Essalmani R., Mayne J, Wickham L, Jin W., Asselin MC, Hamelin J, Varret M, Allard D., Trillard M, Abifadel M, Tebon A., Attie AD, Rader DJ, Boileau C, Brissette L., Chrétien M, Prat A., Seidah NG. NARC-1/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol. J Biol Chem. 2004;279:48865-48875.
5. Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med. 2006;354:1264-1272.
6. Rashid S, Curtis DE, Garuti R, Anderson N.N., Bashmakov Y., Ho YK, Hammer RE, Moon YA, Horton JD Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9. Proc Natl Acad Sci U S A. 2005;102:5374-5379.
7. Abifadel M, Varret M, Rabès JP, Allard D., Ouguerram K, Devillers M, Cruaud C., Benjannet S, Wickham L, Erlich D., Derré A, Villéger L, Farnier M, Beucler I, Bruckert E, Chambaz J, Chanu B, Lecerf JM, Luc G, Moulin P, Weissenbach J, Prat A, Krempf M, Junien C, Seidah NG, Boileau C Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet. 2003;34:154-156.
8. Cohen J, Pertsemlidis A, Kotowski I.K., Graham R., Garcia CK, Hobbs HH Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat Genet. 2005;37:161-165.
9. Seidah NG, Prat A. The biology and therapeutic targeting of the proprotein convertases. Nat Rev Drug Discov. 2012;11:367-383.
10. Seidah NG, Benjannet S, Wickham L., Marcinkiewicz J, Jasmin SB, Stifani S, Basak A., Prat A, Chretien M. The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. Proc Natl Acad Sci U S A. 2003;100:928-933.
11. Dubuc G, Chamberland A, Wassef H., Davignon J, Seidah NG, Bernier L, Prat A. Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol. 2004;24:1454-1459.
12. Pearson WR, Wood T, Zhang Z., Miller W Comparison of DNA sequences with protein sequences. Genomics. 1997;46:24-36.
13. Ason B, Tep S, Davis HR Jr, Xu Y, Tetzloff G, Galinski B., Soriano F, Dubinina N, Zhu L., Stefanni A, Wong KK, Tadin-Strapps M, Bartz S.R., Hubbard B., Ranalletta M, Sachs AB, Flanagan W.M., Strack A., Kuklin NA Improved efficacy for ezetimibe and rosuvastatin by attenuating the induction of PCSK9. J Lipid Res. 2011;52:679-687.
14. Mousavi SA, Berge KE, Leren TP The unique role of proprotein convertase subtilisin/kexin 9 in cholesterol homeostasis. J Intern Med. 2009;266:507-519.
15. Zaid A, Roubtsova A, Essalmani R., Marcinkiewicz J, Chamberland A, Hamelin J., Tremblay M, Jacques H, Jin W., Davignon J, Seidah NG, Prat A. Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration. Hepatology. 2008;48:646-654.
16. Zhang DW, Lagace TA, Garuti R, Zhao Z., McDonald M, Horton JD, Cohen J.C., Hobbs HH Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation. J Biol Chem. 2007;282:18602-18612.
17. Ahmad Z, Adams-Huet B, Chen C., Garg A. Low prevalence of mutations in known loci for autosomal dominant hypercholesterolemia in a multiethnic patient cohort. Circ Cardiovasc Genet. 2012;5:666-675.
18. Brouwers MC, Konrad RJ, van Himbergen TM, Isaacs A, Otokozawa S, Troutt J.S., Schaefer EJ, van Greevenbroek MM, Stalenhoef AF, de Graaf J. Plasma proprotein convertase subtilisin kexin type 9 levels are related to markers of cholesterol synthesis in familial combined hyperlipidemia [published online ahead of print January 17, 2013]. Nutr Metab Cardiovasc Dis. doi:10.1016/j.numecd.2012.1011.1008.
19. Huijgen R, Fouchier SW, Denoun M, Hutten B.A., Vissers MN, Lambert G, Kastelein JJ Plasma levels of PCSK9 and phenotypic variability in familial hypercholesterolemia. J Lipid Res. 2012;53:979-983.
20. Cameron J, Bogsrud MP, Tveten K, Strøm TB, Holven K., Berge KE, Leren T P. Serum levels of proprotein convertase subtilisin/kexin type 9 in subjects with familial hypercholesterolemia indicate that proprotein convertase subtilisin/kexin type 9 is cleared from plasma by low-density lipoprotein receptor-independent pathways. Transl Res. 2012;160:125-130.
21. Maxwell KN, Breslow JL Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype. Proc Natl Acad Sci U S A. 2004;101:7100-7105.
22. Denis M, Marcinkiewicz J, Zaid A., Gauthier D, Poirier S, Lazure C., Seidah NG, Prat A. Gene inactivation of proprotein convertase subtilisin/ kexin type 9 reduces atherosclerosis in mice. Circulation. 2012;125: 894-901.
23. Roubtsova A, Munkonda MN, Awan Z, Marcinkiewicz J., Chamberland A, Lazure C, Cianfone K., Seidah NG, Prat A. Circulating proprotein convertase subtilisin/kexin 9 (PCSK9) regulates VLDLR protein and triglyceride accumulation in visceral adipose tissue. Arterioscler Thromb Vasc Biol. 2011;31:785-791.
24. Sun H, Samarghandi A, Zhang N., Yao Z, Xiong M, Teng BB Proprotein convertase subtilisin/kexin type 9 interacts with apolipoprotein B and prevents its intracellular degradation, irrespective of the low-density lipoprotein receptor. Arterioscler Thromb Vasc Biol. 2012;32:1585-1595.
25. Fan D, Yancey PG, Qiu S, Ding L., Weeber EJ, Linton MF, Fazio S. Selfassociation of human PCSK9 correlates with its LDLR-degrading activity. Biochemistry. 2008;47:1631-1639.
26. Luo Y, Warren L, Xia D., Jensen H, Sand T, Petras S., Qin W, Miller KS, Hawkins J. Function and distribution of circulating human PCSK9 expressed extrahepatically in transgenic mice. J Lipid Res. 2009;50:1581-1588.
27. Alborn WE, Cao G, Careskey H.E., Qian YW, Subramaniam DR, Davies J, Conner E.M., Konrad RJ Serum proprotein convertase subtilisin kexin type 9 is correlated directly with serum LDL cholesterol. Clin Chem. 2007;53:1814-1819.
28. Brown MS, Goldstein JL The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell. 1997;89:331-340.
29. Poirier S, Mayer G, Benjannet S., Bergeron E, Marcinkiewicz J, Nassoury N., Mayer H, Nimpf J, Prat A., Seidah NG The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2. J Biol Chem. 2008;283:2363-2372.
30. Fazio S, Linton MF. Proprotein convertase subtilisin/kexin type 9 as transducer of physiologic influences on cellular cholesterol. A case for resistin. J Am Coll Cardiol. 2012;59:1706-1708.
31. Du F, Hui Y, Zhang M., Linton MF, Fazio D, Fan D. Novel domain interaction regulates secretion of proprotein convertase subtilisin/kexin type 9 (PCSK9) protein. J Biol Chem. 2011;286:43054-43061.
32. Farkas MH, Swift LL, Hasty A.H., Linton MF, Fazio S. The recycling of apolipoprotein E in primary cultures of mouse hepatocytes: evidence for a physiologic connection to high density lipoprotein metabolism. J Biol Chem. 2003;278:9412-9417.
33. Poirier S, Prat A, Marcinkiewicz E., Paquin J, Chitramuthu BP, Baranowski D, Cadieux B., Bennett HP, Seidah NG Implication of the proprotein convertase NARC-1/PCSK9 in the development of the nervous system. J Neurochem. 2006;98:838-850.
34. Grefhorst A, McNutt MC, Lagace T.A., Horton JD Plasma PCSK9 preferentially reduces liver LDL receptors in mice. J Lipid Res. 2008;49:1303-1311.
35. Schmidt RJ, Beyer TP, Bensch W.R., Qian YW, Lin A, Kowala M, Alborn W.E., Konrad RJ, Cao G. Secreted proprotein convertase subtilisin/kexin type 9 reduces both hepatic and extrahepatic low-density lipoprotein receptors in vivo. Biochem Biophys Res Commun. 2008;370:634-640.
36. Lagace TA, Curtis DE, Garuti R, McNutt M.C., Park SW, Prather HB, Anderson NN, Ho Y.K., Hammer RE, Horton JD Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice. J Clin Invest. 2006;116:2995-3005.
37. Konrad RJ, Troutt JS, Cao G. Effects of currently prescribed LDL-C-lowering drugs on PCSK9 and implications for the next generation of LDL-C-lowering agents. Lipids Health Dis. 2011;10:38.
38. Graham MJ, Lemonidis KM, Whipple C.P., Subramaniam A., Monia BP, Crooke ST, Crooke RM Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice. J Lipid Res. 2007;48:763-767.
39. Frank-Kamenetsky M., Grefhorst A, Anderson N.N., Racie TS, Bramlage B, Akinc A, Butler D., Charisse K, Dorkin R, Fan Y., Gamba-Vitalo C, Hadwiger P, Jayaraman M., John M, Jay-aprakash KN, Maier M, Nechev L., Rajeev KG, Read T, Röhl I, Soutschek J., Tan P, Wong J, Wang G, Zimmermann T, de Fougerolles A, Vornlocher HP, Langer R, Anderson DG, Manoharan M, Koteliansky V, Horton JD, Fitzgerald K. Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates. Proc Natl Acad Sci U S A. 2008;105:11915-11920.
40. Stein EA, Gipe D, Bergeron J., Gaudet D, Weiss R, Dufour R., Wu R, Pordy R. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial. Lancet. 2012;380:29-36.
41. Giugliano RP, Kohli P, Rogers W.J., Somaratne R., Huang F, Liu T, Mohanavelu S., Hoffman EB, McDonald ST, Abrahamsen TE, Wasserman S.M., Scott R., Sabatine MS Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study. Lancet. 2012;380:2007-2017.
42. Raal F, Scott R, Somaratne R., Bridges I, Li G, Wasserman S.M., Stein EA Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial. Circulation. 2012;126:2408-2417.
43. Poirier S, Mayer G, Poupon V., McPherson PS, Desjardins R, Ly K, Asselin M.C., Day R., Duclos FJ, Witmer M, Parker R, Prat A., Seidah NG Dissection of the endogenous cellular pathways of PCSK9-induced low density lipoprotein receptor degradation: evidence for an intracellular route. J Biol Chem. 2009;284:28856-28864.
44. Levy E, Ben Djoudi Ouadda A, Spahis S, Sane AT, Garofalo C, Grenier É, Emonnot L, Yara S, Couture P, Beaulieu JF, Ménard D, Seidah NG, Elchebly M. PCSK9 plays a significant role in cholesterol homeostasis and lipid transport in intestinal epithelial cells. Atherosclerosis. 2013;227:297-306.
45. Dubuc G, Tremblay M, Paré G, Jacques H, Hamelin J, Benjannet S, Boulet L, Genest J, Bernier L, Seidah NG, Davignon J. A new method for measurement of total plasma PCSK9: clinical applications. J Lipid Res. 2010;51:140-149.
46. Melone M, Wilsie L, Palyha O., Strack A, Rashid S. Discovery of a new role of human resistin in hepatocyte low-density lipoprotein receptor suppression mediated in part by proprotein convertase subtilisin/kexin type 9. J Am Coll Cardiol. 2012;59:1697-1705.
47. Seidah NG, Poirier S, Denis M., Parker R, Miao B, Mapelli C., Prat A, Wassef H, Davignon J., Hajjar KA, Mayer G. Annexin A2 is a natural extrahepatic inhibitor of the PCSK9-induced LDL receptor degradation. PLoS One. 2012;7:e41865.
48. Kosenko T, Golder M, Leblond G., Weng W, Lagace TA Low-density lipoprotein binds to proprotein convertase subtilisin/kexin type-9 (PCSK9) in human plasma and inhibits PCSK9-mediated LDL receptor degradation. J Biol Chem. 2013;288:8279-8288.
49. Guardamagna O, Restagno G, Rolfo E., Pederiva C, Martini S, Abello F., Baracco V, Pisciotta L, Pino E., Calandra S, Bertolini S. The type of LDLR gene mutation predicts cardiovascular risk in children with familial hypercholesterolemia. J Pediatr. 2009;155:199-204.e2.
50. Raal F, Panz V, Immelman A. Pilcher G. Elevated PCSK9 levels in untreated patients with heterozygous or homozygous familial hypercholesterolemia and the response to high-dose statin therapy. J Am Heart Assoc. 2013; doi: 10.1161/JAHA.112.000028.